Status:
COMPLETED
Pomegranate Juice and Metabolic Syndrome
Lead Sponsor:
Urmia University of Medical Sciences
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome.
Detailed Description
The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome in shabestar.
Eligibility Criteria
Inclusion
- presence of ≥3 of the following diagnostic of MetS:
- serum TGs of at least 150 mg/dL,
- waist circumference of more than 102 cm (40 in) in men and more than 88 cm (35 in) in women,
- high-density lipoprotein (HDL) level less than 40 mg/dL in men and less than 50 mg/dL in women,
- blood pressure 135/85 mm Hg or higher, or
- fasting glucose 100 mg/dL or Higher
Exclusion
- liver cirrhosis,
- chronic pancreatitis,
- gastrointestinal or connective diseases,
- kidney stones, or
- renal failure,
- alcohol Consumption,
- having an allergy to pomegranate juice,
- a change in diet,
- the large increase in LDL so that required drug treatment.
- use of statins of fibrates, corticosteroids, nitrates, acetyl-salicylic acid or other anti-platelet drugs, oral hypoglycemic drugs, nonsteroidal anti-inflammatory drugs, or drugs interfering with coagulation;
- pregnancy or lactation in the past 6 mo, supplementation with vitamins or antioxidants
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02298621
Start Date
January 1 2013
End Date
February 1 2013
Last Update
November 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urmia University of Medical Sciences
Urmia, Iran, +98